Aug 7, 2026
Christian D. Menefee- Amount
- $15,001 to $50,000
- Filed
- Aug 7, 2026
Congress ticker disclosure profile
As of August 6 at 8:00 PM EDT
Public STOCK Act rows mentioning
A factual page for public Congressional disclosures that reference PINS. Veridion shows filed rows, disclosed amount ranges, dates, and source links. It does not imply motive or wrongdoing.
90d rows
1
Feed lifetime
16
Member filers
6
Disclosed ranges
$275K
Most active member desks
11 sells vs 5 buys
Latest trade Aug 7, 2026
Aug 7, 2026
Christian D. MenefeeMay 28, 2026
Christian D. MenefeeFeb 23, 2026
Christian D. MenefeeDec 16, 2025
Julia LetlowApr 28, 2023
John W. HickenlooperJan 14, 2022
David RouzerAug 27, 2021
Josh GottheimerAug 2, 2021
Josh GottheimerJul 13, 2021
Josh GottheimerNov 16, 2020
Thomas R. Suozzi| Date | Member | Action | Amount | Filed | Receipt |
|---|---|---|---|---|---|
| Aug 7, 2026 | Christian D. Menefee | Sell | $15,001 to $50,000 | Aug 7, 2026 | Open card |
| May 28, 2026 | Christian D. Menefee | Sell | $15,001 to $50,000 | Jun 1, 2026 | Open card |
| Feb 23, 2026 | Christian D. Menefee | Sell | $15,001 to $50,000 | Jun 1, 2026 | Open card |
| Dec 16, 2025 | Julia Letlow | Sell | $1,001 to $15,000 | Jan 13, 2026 | Open card |
| Apr 28, 2023 | John W. Hickenlooper | Sell | $1,001 to $15,000 | May 15, 2023 | Open card |
| Jan 14, 2022 | David Rouzer | Sell | $1,001 to $15,000 | Jan 17, 2022 | Open card |
| Aug 27, 2021 | Josh Gottheimer | Sell | $1,001 to $15,000 | Sep 20, 2021 | Open card |
| Aug 2, 2021 | Josh Gottheimer | Sell | $1,001 to $15,000 | Sep 20, 2021 | Open card |
| Jul 13, 2021 | Josh Gottheimer | Sell | $1,001 to $15,000 | Aug 9, 2021 | Open card |
| Nov 16, 2020 | Thomas R. Suozzi | Sell | $15,001 to $50,000 | Sep 23, 2021 | Open card |
Source creed
This page is assembled from public STOCK Act disclosure records in the Veridion warehouse. 16 of 16 filed rows include disclosed amount ranges (100%). Rows without ranges stay labeled. Identification only; it does not imply motive or wrongdoing.
Disclosure findings, methodology notes, and product updates when we have them. No fixed schedule yet. No advertising list resale.